The major advantage of the proposed therapeutic approach is that anti-CTLA4 is a well-established, FDA-approved oncologic medication used across the vast majority of solid tumor indications that may necessitate a lymphadenectomy (namely breast, renal and cervical cancer or melanoma), which increases lymphedema risk. Here, CTLA4 is linked to melanoma.